What are Antibody-drug Conjugates?-Reference-Cited by-同舟云学术

What are Antibody-drug Conjugates?

Published:2019-03-22 Issue: Volume: Page:
ISSN:2327-0152
Container-title:ADC Review / Journal of Antibody-drug Conjugates
language:
Short-container-title:JADC

Author:

Hofland Peter^ORCID, ,Portillo Sonia,

Abstract

Antibody-drug Conjugates or ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

Publisher

Sunvalley Communication

Subject

Industrial and Manufacturing Engineering

Reference8 articles.

1. [1] Resources for Clinicians. ADC Review / Journal of Antibody-drug Conjugates. Online. Last accesses July 19, 2020.

2. [2] Ducry L. Challenges in the development and manufacturing of antibody-drug conjugates. Methods Mol Biol. 2012;899:489-97. doi: 10.1007/978-1-61779-921-1_29. PMID: 22735971.

3. [3] Rohrer T. Biotechnology + Chemistry = Antibody-Drug Conjugates. Lonza. Last accesses July 19, 2020.

4. [4] Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17(6):e254-e262. doi: 10.1016/S1470-2045(16)30030-4. PMID: 27299281; PMCID: PMC6601617.

5. [5] Jerjian TV, Glode AE, Thompson LA, O'Bryant CL. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. Pharmacotherapy. 2016 Jan;36(1):99-116. doi: 10.1002/phar.1687. PMID: 26799352.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy;ADC Review / Journal of Antibody-drug Conjugates;2020-04-07